Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023

Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD

Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result